Putin decorates commandoes for two-day face-to-face clash with militants in SyriaRussian Politics & Diplomacy May 24, 18:31
Experts say rising military spending to push Europe to reconsider NATO’s roleRussian Politics & Diplomacy May 24, 17:56
Poll shows 25% of Russians expect headway in ties with France during Macron’s presidencySociety & Culture May 24, 17:33
Former Finnish PM points to signs of improvement in Russia-West relationsWorld May 24, 17:20
Russia's legendary Su-27 jet fighter marks the 40th anniversary of its first flightMilitary & Defense May 24, 17:19
Russian lawmaker comments on US decision to end military subsidies to UkraineRussian Politics & Diplomacy May 24, 16:30
Nine Russian missile regiments rearmed with advanced ICBM systemsMilitary & Defense May 24, 16:01
Perm session completes cycle of regional offsite events in run-up to SPIEF 2017Press Releases May 24, 15:38
Ka-52 helicopters to have advanced weapon targeting systemMilitary & Defense May 24, 15:09
NOVOSIBIRSK, June 9. /TASS/. A new vaccine to protect against Ebola virus disease developed by Russia’s Vector research center of virology and biotechnology has successfully undergone the first stage of clinical tests, the acting director general of the research center told reporters on the sidelines of the international forum for technological development on Thursday.
"The first phase of clinical tests has been completed. It is now on approval at the Russian Ministry of Healthcare. We are waiting for a second phase," Valery Mikheyev said.
According to the World Health Organization (WHO), more than 11,300 people have died from Ebola in West Africa, primarily in Guinea, Sierra Leone and Liberia. More than 28,600 were infected. In January, Russia informed the WHO executive committee about its anti-Ebola vaccines.
The World Health Organization describes Ebola virus disease (formerly known as Ebola haemorrhagic fever) as "a severe, often fatal illness, with a case fatality rate of up to 90%." Until now, there has been no known cure or vaccine for the disease. The only treatment offered is "supportive intensive care." During an outbreak, those at higher risk of infection are health workers, family members and others in close contact with sick people and deceased patients.